Archer Investment Corp Has $2.27 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Archer Investment Corp boosted its position in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 4th quarter, HoldingsChannel reports. The firm owned 14,484 shares of the company’s stock after acquiring an additional 72 shares during the period. Johnson & Johnson makes up about 0.7% of Archer Investment Corp’s portfolio, making the stock its 29th largest position. Archer Investment Corp’s holdings in Johnson & Johnson were worth $2,270,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Johnson & Johnson by 281.6% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 14,436 shares of the company’s stock valued at $2,261,000 after purchasing an additional 10,653 shares during the last quarter. Rakuten Securities Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $691,000. Sloy Dahl & Holst LLC lifted its stake in Johnson & Johnson by 7.5% in the 4th quarter. Sloy Dahl & Holst LLC now owns 5,156 shares of the company’s stock valued at $808,000 after purchasing an additional 360 shares during the last quarter. Guidance Point Advisors LLC raised its holdings in Johnson & Johnson by 4.1% in the 4th quarter. Guidance Point Advisors LLC now owns 1,843 shares of the company’s stock valued at $289,000 after acquiring an additional 73 shares during the period. Finally, Tyche Wealth Partners LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $5,764,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 0.8 %

Shares of JNJ opened at $149.12 on Tuesday. The firm’s 50 day moving average is $155.97 and its 200-day moving average is $155.57. The stock has a market capitalization of $359.35 billion, a PE ratio of 9.30, a P/E/G ratio of 2.44 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $2.68 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.33%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 29.68%.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 17th. Raymond James increased their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.